248.20
+1.64%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beigene
Its shares trade on HKEX under the ticker 6160.HK. It has been listed since 3 February 2016. In the fiscal year to 31 December 2025, it reported revenue of $43.03bn and net income of $2.31bn. At that date it held total assets of $64.45bn and shareholders' equity of $34.14bn.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company is headquartered in Beijing, Beijing. The company went IPO on 2016-02-03. The firm is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The firm's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Feb 2016
- Employees
- 5,300
Leadership
Pay as last reported
- Mr. John OylerCo-Founder, Executive Chairman of the Board, Chief Executive Officer, since 2010$16.7m
- Dr. Xiaobin WuPresident, Chief Operating Officer, General Manager - China
- Dr. Xiaodong WangCo-Founder, Non-Executive Director$4.3m
- MR. Aaron RosenbergChief Financial Officer, since 2024
- Mr. Chan LeeSenior Vice President, General Counsel
- Mr. Giancarlo BenelliSenior Vice President, Head of Europe
- Mr. Matthew ShaulisGeneral Manager, North America
- Dr. Lai WangGlobal Head of R&D
- Mr. Ranjeev KrishanaLead Non-Executive Independent Director$492,000
- Ms. Shalini SharpDirector
- Dr. Olivier BrandicourtIndependent Non-Executive Director
- Dr. Han DuganNon-Executive Independent Director$516,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 75
- Social
- 99
- Governance
- 54
- Direct emissions (scope 1)
- 3,547 t
- Energy emissions (scope 2)
- 81,095 t
- Value chain emissions (scope 3)
- 662,688 t
- Women in the workforce
- 58.2%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beigene Ltd has a strong portfolio of oncology drug candidates, which positions the company well in the growing market for cancer treatments.
- The company has established partnerships with major international pharmaceutical companies, enabling it to access resources and expertise that can help accelerate drug development and commercialization.
- Beigene Ltd has a strong financial position, with a solid cash reserve and access to capital markets, providing the necessary resources for research and development, as well as potential acquisitions.
Weaknesses
- The company heavily relies on a few key drug candidates, which poses a risk in case of any setbacks in the clinical trials or regulatory approval processes.
- Beigene Ltd currently has a limited presence in international markets, particularly outside of Asia, which may restrict its commercial opportunities and revenue potential.
- The company may face challenges in effectively managing its rapid growth, including scaling up its operations and maintaining a cohesive organizational culture.
Opportunities
- The increasing prevalence of cancer globally presents a significant growth opportunity for Beigene Ltd, given its focus on oncology therapeutics.
- Expansion into new markets, such as Europe and the United States, can provide access to larger patient populations and enhance the company's revenue potential.
- Collaborations with academic institutions and research organizations can foster innovation and help Beigene Ltd stay at the forefront of cancer research and development.
Threats
- Intense competition within the oncology drug market from both established pharmaceutical companies and emerging biotech firms can limit Beigene Ltd's market share and pricing power.
- Evolving regulatory requirements and the potential for delays in drug approvals can hinder the company's ability to bring new therapeutics to market in a timely manner.
- The possibility of unforeseen adverse events during clinical trials or safety concerns post-commercialization can impact the company's reputation and investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.